Simcere Pharmaceutical Group Announces Resignation of Dr. Peng Wang, Chief Scientific Officer

Simcere Pharmaceutical Group ("Simcere" or the "Company")

, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the resignation of Dr. Peng Wang, Chief Scientific Officer of the Company, effective from May 29, 2013. Dr. Wang resigned for personal reasons. His resignation has been approved by the Company. Mr. Hongquan Liu, the Chief Executive Officer of Simcere, said, "We thank Dr. Wang for his contribution to our research and development efforts and we wish him all the best in the future." About Simcere Pharmaceutical Group Simcere Pharmaceutical Group ("Simcere" or the "Company")

is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases, and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com. Investor and Media Contacts: Email: ir@simcere.com In Nanjing: Jie Liu D'Elia Vice President Simcere Pharmaceutical Group Tel: 86-25-8556-6666*8857 In the United States: Cindy Zheng Brunswick Group LLC Tel: 1-212-333-3810   In Beijing: Yue Yu Brunswick